Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-1898 in radioiodine-refractory differentiated thyroid cancer after prior TKI failure
CTR20233031Phase 2Active
- Sponsor
- Beijing Scitech-MQ Pharmaceuticals Limited
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ACC-1898 in well-differentiated thyroid cancer (WDTC), sponsored by Beijing Scitech-MQ Pharmaceuticals Limited. Started Jan 2024; status: active.
02
Drugs
ACC-1898
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20233031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233031.